Combined sprint and resistance training abrogates age differences in somatotropic hormones

Maha Sellami, Wissem Dhahbi, Lawrence D. Hayes, Johnny Padulo, Fatma Rhibi, Hanen Djemail, Anis Chaouachi

To cite this version:

Maha Sellami, Wissem Dhahbi, Lawrence D. Hayes, Johnny Padulo, Fatma Rhibi, et al.. Combined sprint and resistance training abrogates age differences in somatotropic hormones. PLoS ONE, Public Library of Science, 2017, 12 (8), pp.e0183184. 10.1371/journal.pone.0183184. hal-01585979

HAL Id: hal-01585979
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01585979
Submitted on 28 Jun 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Combined sprint and resistance training abrogates age differences in somatotropic hormones

Maha Sellami¹, Wissem Dhabhi¹, Lawrence D. Hayes², Johnny Padulo¹,³,⁴*, Fatma Rhibi⁵, Hanen Djemail⁶, Anis Chaouachi¹

¹ Tunisian Research Laboratory “Sport Performance Optimization” National Center of Medicine and Science in Sports, Tunis, Tunisia, ² Active Ageing Research Group, Department of Medical and Sport Sciences, University of Cumbria, Bowerham Road, Lancaster, United Kingdom, ³ University eCampus, Novedrate, Italy, ⁴ Faculty of Kinesiology, University of Split, Split, Croatia, ⁵ Movement, Sport, Health and Sciences Laboratory (M2S), University of Rennes 2, Rennes, France, ⁶ Military Hospital of Instruction of Tunis, Department of Endocrinology, Tunis, Tunisia

* sportcinetic@gmail.com

Abstract

The aim of this investigation was to compare serum growth hormone (GH), insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) in response to a combined sprint and resistance training (CSRT) program in young and middle-aged men. Thirty-eight healthy, moderately trained men participated in this study. Young and middle-aged men were randomly assigned to a young training group (YT = 10, 21.4±1.2yrs) or a young control group (YC = 9, 21.6±1.8yrs), a middle-aged training group (MAT = 10, 40.4±2.1yrs) or a middle-aged control group (MAC = 9, 40.5±1.8yrs). Participants performed the Wingate Anaerobic Test (WAnT) before and after a 13-week CSRT program (three sessions per week). Blood samples were collected at rest, after warm-up, immediately post-WAnT, and 10 min post-WAnT. CSRT induced increases in GH at rest and in response to the WAnT in YT and MAT (P<0.05). CSRT-induced increases were observed for IGF-1 and IGFBP-3 at rest in MAT only (P<0.05). Pre-training, GH, IGF-1 and IGFBP-3 were significantly higher at rest and in response to the WAnT in young participants as compared to their middle-aged counterparts (P<0.05). Post-training, YT and MAT had comparable basal GH (P>0.05). In response to the WAnT, amelioration of the age-effect was observed between YT and MAT for IGF-1 and IGF-1/IGFBP-3 ratio following CSRT (P>0.05). These data suggest that CSRT increases the activity of the GH/IGF-1 axis at rest and in response to the WAnT in young and middle-aged men. In addition, CSRT reduces the normal age-related decline of somatotropic hormones in middle-age men.

Introduction

The aging process is associated with a precipitous decline in skeletal muscle mass and strength, estimated as 35–40% between 20 and 80 yrs[1], with an accelerated decline after 50 yrs[2].
Moreover, cross-sectional studies have observed that the ability to develop muscle strength and power declines from 40 to 80 yrs\cite{3, 4}. It has been suggested that reduced muscle function may result from neural degeneration combined with muscle atrophy. Muscle atrophy occurs when muscle protein degradation exceeds muscle protein synthesis. Said muscle atrophy may be partly attributable to a reduction in anabolic hormone production \cite{5}, whilst age-associated physical inactivity may exacerbate muscle loss. Moreover, the reduction in systemic anabolic hormones may be further exacerbated by physical inactivity in older adults\cite{6}.

The systemic reduction in insulin-like growth factor-1 (IGF-1) has been attributed, in part, to decreased secretion of growth hormone (GH), the main secretagogue of IGF-1. GH secretion reduces ~14% per decade after the second decade \cite{7}, and reaches, by the age of ~60 yrs, half of the GH secretion of younger counterparts (20–30 yrs\cite{8}). IGF-1, the main stimulated protein downstream of GH, concomitantly decreases with age (~10% per decade) and is associated with cell proliferation, cell differentiation, energy metabolism and prevention of apoptosis \cite{9}. Most IGF-1 circulates in the blood bound to IGF-binding proteins (IGFBPs) which mediate bioavailability into tissue \cite{10}. The most abundant is the insulin-like growth factor-binding protein 3 (IGFBP-3), which carries 90–95% of IGF-1 in circulation \cite{11}. Hence, it is necessary to consider IGFBP-3 when total serum IGF-1 is determined to provide a measure of bioavailability. Serum IGFBP-3 is regulated by GH signaling \cite{12, 13} and reduced with advanced age \cite{14}. The main function of IGFBP-3 is to permit IGF-1 transport and to regulate anti-proliferative and apoptotic effects through cell surface receptor by opposing IGF-1 action \cite{15, 16}. Moreover, IGFBP-3 is a valuable tool for diagnosis of GH perturbation during the aging process \cite{17}.

Because GH naturally declines with age, there has been increasing interest in the role of GH as an anti-aging factor, and some evidence suggests GH administration increases fatty acid oxidation, protein synthesis and, consequently, lean body mass \cite{18}. To date, however, there have been no approved clinical studies to assess the effects of GH administration on muscle mass loss with aging. In fact, GH administration has been shown to have no effect on muscle function in healthy aged men and women \cite{19}. As GH administration is widely used as a muscle mass and performance enhancer \cite{20}, whether exercise could be a nonpharmacological intervention to enhance GH and subsequently muscle mass and muscle strength, requires further investigation.

Whilst acute exercise-induced elevations in GH and IGF-1 are consistently reported \cite{20–26}, the effect of long-term exercise training on basal GH and IGF-1 secretion is more ambiguous. It is well known that GH response exercise training depends on several factors including age, diet, stress, or training intensity \cite{20, 27}. Metabolic (i.e glucose) and hormonal (i.e. catecholamines, cortisol, testosterone) factors also influence GH \cite{28–30} which in turn are also dependent upon exercise intensity and training type\cite{31, 32}. In this context, increase of these hormones is greater following anaerobic training in young and middle-aged trained men \cite{6, 31–33}. Moreover, Nevill et al. \cite{34} suggested that serum GH response to treadmill running was greater in sprinters compared to endurance athletes. In addition, endurance training (running for eight weeks) resulted in increased systemic IGF-1 (+15%) in subjects aged ~66 yrs \cite{35}, yet Vitiello, Wilkinson \cite{36} observed no perturbation in IGF-1 amongst moderately and well-trained endurance athletes aged ~69 yrs. As such, intensive training using sprint or resistance training appears necessary to induce changes to serum GH. Moreover, numerous studies suggest sprint training may elicits greater increase in muscle strength than the endurance training\cite{31, 34}. Borst et al. \cite{37} suggested that 25 weeks’ resistance training in middle-aged men (~37 yrs) resulted in increased GH and IGF-1 with increase in strength performances. However, Adams et al. \cite{38} suggested it necessary to add different types of exercise to resistance exercise in order to obtain higher muscle power during sprint exercise. In fact, some
authors suggest combined sprint and resistance training is more efficient than sprint training only [39] or resistance training only [40].

Most existing GH and IGF-1 exercise studies have focused on young (~20 yrs) and elderly (>65 yrs) subjects. Therefore, there is a paucity of data concerning the effect of concurrent exercise training (sprint interval and resistance exercises) on somatotropic hormones in adults ~40 yrs. Thus, we examined the effect of 13 weeks’ concurrent training on GH, IGF-1, and IGFBP-3 in young (~20 yrs) and middle-aged (~40 yrs) men before and after supramaximal exercise. We hypothesized a priori that younger participants would have greater GH, IGF-1, and IGFBP-3. Moreover, we hypothesized that training would increase somatotropic hormone concentrations in both age groups.

Materials and methods
Participants

Military Participants reviewed and signed consent forms specifically approved by the “Department of staff and training committee” (Bouchoucha, Tunisia). The “Department of staff and training committee” approved the entire study design which has been conducted according to the principles expressed in the Declaration of Helsinki.

During the design of the study, statistical power analysis was carried out to calculate sample size. This procedure showed that nine subjects for each of four groups were needed to achieve a statistical power of 80% to detect a small effect (d = 0.29) when assessed by four-factor mixed analysis of variance (ANOVA) with a level of significance of 5%. Therefore, thirty-eight healthy, moderately trained men (military participants) were recruited for participation in the present investigation.

To assess the physical condition of military participants, we used an adapted version of the Baecke questionnaire [41]. Before the study, subjects performed 1 h of running and leisure-time physical activity at least three times per week (180 min/week -1). Inclusion criteria included the absence of the following: contraindications to maximal exercise testing (e.g., cardiovascular or pulmonary disease); endocrine disorders; metabolic syndrome symptoms (e.g., hypertension, impaired fasting glucose). Following recruitment and familiarization, participants completed medical history and dietary questionnaires. Thereafter, young and middle-aged participants were randomized to receive 13 weeks’ combined sprint and resistance training (CSRT), or control. Therefore, four groups existed: a young training group (YT = 10; age 21.4±1.2 yrs, body height 178.3±3.2 cm, body mass 74.4±5.4 kg), a young control group (YC = 9; age 21.6±1.8 yrs, body height 179.7±6.4 cm, body mass 69.5±7.3 kg), a middle-aged training group (MAT = 10; age 40.4±2.1 yrs, body height 175.8±5.2 cm, body mass 78.4±5.2 kg) and a middle-aged control group (MAC = 9; 40.5±1.8 yrs, body height 177.3±4.4 cm, body mass 76.6±3.9 kg).

A conventional dietary survey was conducted by a sports nutritionist of the Department of Physical Education and Military Sport to monitor individual participants’ diets over the 13 weeks. Participants were asked to abstain from high glycemic loads, saturated and trans-fatty acids, caffeine, alcohol, drugs, vitamins or supplements, and low-fiber diets for the duration of the study.

Before training (during the medical examination), subjects were familiarized with testing procedures to negate learning effect. Participants avoided physical activity for 48 h preceding each test. The testing period was divided into two phases: before (P1), and after (P2), training. Each period lasted seven days and included anthropometric measurements and two consecutive laboratory visits separated by 48 h. The second phase (P2) began 48 h after training cessation and finished seven days later. All tests were performed in the morning 2h postprandial...
(standard breakfast: 10 kcal·kg⁻¹, 55% carbohydrate, 33% lipids and 12% protein). Anthropometric parameters were measured on the morning of the first day. Measurement of body mass (kg) and height (cm) were taken from all participants. Body mass was measured to the nearest 0.1 kg, with subjects in light clothing and without shoes, using electronic scales (Kern, MFB 150K100). Height was determined to the nearest 0.5 cm with a measuring tape fixed to the wall. Subsequently, skin-folds were measured using Harpenden calipers (Harpenden skinfold calipers, Sweden). Percentage body fat was determined by the four skin-folds method [42].

Exercise tests

During the medical exam, participants performed the Astrand-Ryhming test [43] on a cycle ergometer (Monark Ergoline: ER900, Ergoline, Jaeger, Würzburg, Germany) to estimate maximal oxygen uptake (VO₂max). Heart rate (S810, Polar Instruments Inc., Oulu, Finland) and rating of perceived exertion (RPE; Borg 1973) was recorded at the end of each stage. A maximal test was confirmed when participants achieved a minimum of any three of the following criteria: volitional exhaustion, peak heart rate within 10 beats of age predicted maximum, blood lactate above 8 mmol·L⁻¹, final RPE >18 on Borg scale.

48 hours later (day 2), subjects performed a force-velocity (F/V) test [44] on a cycle ergometer (Monark Ergomedic 894E Peak Bike, Monark, Varberg, Sweden). The test began 5 min after warm-up (15 min at a power output corresponding to 50% estimated VO₂max). This test comprised five short trials (6 s) against increasing resistance (2 kg each sprint) until the velocity began to decrease during the 6 s trials. Recovery time between each trial was 5 min. The highest pedaling cadence recorded after each trial was collected from a photoelectric cell fixed on the wheel of the cycle ergometer and connected to a computer. The load that permitted the highest peak power output was used for the Wingate Anaerobic Test (WAnT).

48 hours later (day 3), subjects performed the WAnT on a mechanically-braked Monark cycle ergometer (Monark Ergomedic 894E Peak Bike, Monark, Varberg, Sweden). The test commenced 5 min after warm-up. Subjects were asked to cycle maximally for 30 s. Maximal power during the trial was considered as the highest value (W_peak), while average power during the WAnT was considered as mean power (W_mean).

Before the F/V test and the WAnT, a heart rate monitor (S810, Polar Instruments Inc., Oulu, Finland) was used to control exercise and warm-up intensity. Warm-up intensity was calculated using the re-engineered equation of Swain et al. [45] to determine the maximum heart rate percentage (%MHR) using %VO₂max:

\[
\% \text{MHR} = 0.6463 \times \% \text{VO}_2\text{max} + 37.182
\]

Where %MHR is the percentage of maximal heart rate and %VO₂max is the percentage of estimated maximal oxygen uptake.

A pilot study was carried out to ensure the reproducibility and sensitivity of W_peak and W_mean indices, using two measurements of 10 subjects in a single day. Both indices showed excellent intraclass correlation coefficients (ICC = 0.91–0.94), small standard error of measurements (SEM; 3.41–4.56%, <5%) and a small coefficient of variation (CV; <5%).

Similar testing procedures have been used in numerous studies involving normal weight adolescent [46], young adults [47–49], and middle-aged men [32,50–53]. The standard WAnT procedure has limitations because factors such as i) active muscle mass volume and ii) exercise bioenergetics tend to alter maximal power output (Pmax) (for review see Driss and Vanderwalle [54]. Standardized WAnT intensity has previously failed to utilize an optimal load due to heterogenous F/V profiles of individuals [44, 55–58]. According to Driss and Vanderwalle [54], the load during a standardized WAnT underestimates Pmax in normal weight and powerful
adults. Moreover, the load used by researchers at the Wingate Institute was modified several times: 75g kg\(^{-1}\) body weight\[59\], then 67g kg\(^{-1}\)\[60\], then 75g kg\(^{-1}\)\[61\].

**Exercise training program**

Trained subjects (YT and MAT) underwent 13 weeks’ CSRT as previously described \[53\]. Briefly, CSRT involved three consecutive sessions separated by 48 h: sprint running sessions (13 sessions), resistance training sessions (13 sessions) and sprint cycling sessions (13 sessions). Sessions were performed during the morning and lasted no longer than 70 min, inclusive of 15 min warm-up (jogging and stretching) and 15 min cool-down (jogging and stretching).

During the first training session, YT and MAT performed a sprint running session, which included three to five sets of three to five short bouts at maximum velocity. A passive recovery of 2–3 min was permitted between each set.

Forty-eight hours later, YT and MAT performed the resistance training session, which included five to six exercises targeting all major muscle groups (squat with Smith machine, machine leg extension, machine leg curl, calf raises over a step, triceps pushdown with cable machine, bicep preacher curl, and bench press. The load used during these exercises (% of one-repetition maximum [1-RM]) was progressively increased from 40 to 65% of 1-RM, and increased by 5% of 1-RM per week\[62\]. To produce maximal power output (i.e., velocity \times load), the positive phase \[63\] of each exercise was performed as fast as possible \[64\]. The number of repetitions was maintained as 10–15 per set, and the number of sets increased from three to four over the training period. Therefore, training volume increased progressively during the CSRT program. Rest period between sets were 3–5 min for upper body muscles\[65\] and at least 1 min for lower limbs to allow for tolerance to increased repetitions. To adjust loads during resistance training sessions, we determined muscle strength using a 1-RM for the six resistance exercises, before CSRT, during the sixth week and post-CSRT. All subjects were familiarized with the test procedures. Ten-minute warm-up (stretching and cycling at 50% VO\(_{2}\)\(_{\text{max}}\) preceded the test. After 5 min rest, subjects performed 5 repetitions at approximately 50% of the estimated 1-RM followed by another set of 3 repetitions at 70% of the estimated 1-RM. Subjects then performed one repetition of progressively heavier loads until failure. Maximum strength was determined as the maximum load that could be lifted once with proper technique.

During the third training session, subjects performed a sprint cycling session. Each series comprised three to five repetitions of 10–30 s. The 10–30 s trials were performed maximally. Subjects recovered actively (at a power output corresponding to 50% VO\(_{2}\)\(_{\text{max}}\) for 3–5 min between each sprint.

**Blood sampling and analysis**

Upon the participants’ arrival, a heparinized catheter (Insyte-W, 1.1 mm o.d. \times 30 mm) was inserted into an antecubital vein, following sitting for 20 min. Blood was obtained between 08:00 and 09:00 h. to control for diurnal variation on visit two of exercise testing. Venous blood samples were drawn at four times: at rest (\(t_0\) after 20 min sitting on the bike), after warm-up (\(t_w\)), immediately post-WAnT (\(t_{w0}\)) and 10 min post-WAnT (\(t_{10}\)). For each sample, 10 mL of blood was collected in tubes containing ethylenediaminetetraacetic acid (EDTA) to determine concentrations of serumGH, IGF-1, and IGFBP-3. Samples were centrifuged immediately (at 3000 rpm for 15 min at 4°C), before being divided into appropriate aliquots and stored at -80°C for later analysis.

Blood sample was collected from the finger (20μL) at the third minute post-WAnT and placed in Eppendorfs for measurement of peak blood lactate concentration ([La]_{peak}). Blood
lactate concentration was determined using an enzymatic lactate analyzer (Microzym, Cetrix, France).

GH was assayed by chemiluminescence (Immulite, Diagnostic Products Corp., Los Angeles, CA, USA). The GH assay sensitivity limit was 0.1 ng·ml⁻¹ and inter- and intra-assay CV was 5.7–10% and 4.9–8.3% respectively. IGF-1 was measured using the non-extraction IGF-1 immunoradiometric assay (IRMA) kit (Diagnostic Systems Laboratories, Webster, TX, USA). The theoretical sensitivity, or minimum detection limit, as calculated by interpolation of the mean plus two standard deviations (SD) of 20 standard replicas 0 ng·ml⁻¹ was 2 ng·ml⁻¹. The inter-assay CV was 7.4% and 4.2% at concentrations of 35.5 ng·ml⁻¹ and 383.9 ng·ml⁻¹ respectively. The intra-assay CV was 6.8% and 6.3% for mean concentrations of 34.03 ng·ml⁻¹ and 373.86 ng·ml⁻¹ respectively. IGFBP-3 concentrations were measured by using the non-extraction IRMA kit (Diagnostic Systems Laboratories, Webster, TX, USA). The lower threshold of detection, calculated as the mean two SD of 22 standard replica 0 ng·ml⁻¹ of IGFBP-3, was ~0.5 ng·ml⁻¹. The intra-assay CV was 1.8% and 3.9% for mean concentrations of 82.7 ng·ml⁻¹ and 7.4 ng·ml⁻¹ respectively. The inter-assay CV was 1.9% and 0.6% for mean concentrations of 76.9 ng·ml⁻¹ and 8.0 ng·ml⁻¹ respectively. All biochemical assays were run in duplicate.

Statistical analysis

Data were analyzed using SPSS version 23.0 for Windows (SPSS, Inc. Chicago, IL, USA). Means and standard deviations (SD) were calculated after verifying normality of distributions using the Kolmogorov-Smirnov procedure. For anthropometric, physiological and physical performance, along with area under the curve (AUC), data were analyzed using a multifactorial three-way (time [P1, P2] × age [young, middle-aged] × group [trained, control]) ANOVA.

Hormone responses were analyzed using a four-factor ANOVA (time [P1, P2] × Wingate time [warm-up, immediately post-WAnT and 10 min post-WAnT] × age [young, middle-aged] × group [trained, control]).

Total AUCs for GH, IGF-1, and IGFBP-3 were calculated to determine the total hormone exposure over the measured period. It simplified the statistical analyses by rendering the multivariate results into univariate result [66]. The AUC is determined using the linear trapezoidal method which uses linear interpolation between data points.

Greenhouse-Geisser corrections were used when the assumption of sphericity (Mauchly’s test) was violated. To help protect against type II errors, an estimate of power (ω) and effect size (η²_p) were calculated. Bonferroni-adjusted pairwise post hoc comparisons were performed where appropriate. Pearson’s product-moment correlation coefficients were calculated to assess relationships between variables. Significance level was set a priori at P<0.05.

Results

Anthropometric data

At P1, there was a significant main effect of age for body mass (F = 4.99, P = 0.03, η²_p = 0.13, ω = 0.58), whereby YT and YC were significantly lighter than MAT and MAC (P<0.05). At P2, both training groups experienced a decrease in body mass from P1 (72.4±5.2 and 76.2±5.4 kg for YT, and MAT respectively [P<0.05]), whereas the control groups’ body mass was not significantly different from P1 (P>0.05). The main effect of time (from P1 to P2) was significant (F = 8.85, P<0.01, η²_p = 0.21, ω = 0.82) after CSRT.

At P1, there was no main effect of age for body fat percentage (11.7±1.4%, 11.3±1.8%, 12.9 ±1.2%, and 12.4±2.2% for YT, YC, MAT, and MAC respectively; F = 2.45, P = 0.13, η²_p = 0.07, ω = 0.33). At P2, both training groups experienced a decrease in body fat from P1 (10.2±0.8% and 11.2±1.4% for YT, and MAT respectively; F = 14.52, P<0.01, η²_p = 0.30, ω = 0.96), while
control groups’ body fat percentages were not significantly different from P1 (F = 2.16, P > 0.05). We also observed significant interaction between Time × Group (F = 5.82, P = 0.02, η²_p = 0.15, ŷ = 0.65).

At P1, no significant main effect of age for fat-free mass (FFM) was observed (65.2 ± 5.5 kg, 64.1 ± 4.5 kg, 62.1 ± 5.2 kg, and 60.4 ± 3.2 kg for YT, YC, MAT, and MAC respectively with F = 2.14, P = 0.15, η²_p = 0.06, ŷ = 0.30). At P2, FFM was 66.1 ± 5.1 kg, 64.6 ± 5.7 kg, 63.8 ± 5.4 kg, and 61.4 ± 4.4 kg for YT, YC, MAT, and MAC respectively. No group experienced a significant change in FFM between P1 and P2 (P > 0.05) and there was no main effect of time (F = 0.68, P = 0.41, η²_p = 0.02, ŷ = 0.13).

Physical performance and physiological response
The results of the WAnT are displayed in Table 1. There was a significant main effect of age in W_peak (F = 5.98, P = 0.02, η²_p = 0.15, ŷ = 0.66). At P1, W_peak was significantly higher in young groups compared to middle-aged groups (P < 0.05). However, this main effect of age for W_peak at P1 (P < 0.001) was ameliorated at P2 (P > 0.05).

In addition, W_peak increased significantly after training in both YT and MAT (P < 0.05). At P2, trained groups exhibited significantly (P < 0.05) higher W_peak compared to control groups. Significant interaction between Time × Group was registered in W_peak (F = 4.92, P = 0.03, η²_p = 0.13, ŷ = 0.58). No main effect of age or time (P > 0.05) were observed for W_mean.

[La]_peak increased significantly (P < 0.05) in trained groups (YT and MAT) after CSRT (Table 1). A significant main effect of time was observed (F = 18.93, P < 0.001, η²_p = 0.35) for [La]_peak, whilst there was no main effect of age (F = 1.38, P = 0.25, η²_p = 0.04, ŷ = 0.21) between groups at P2.

For VO₂max, we observed a significant main effect of time (F = 18.35, P < 0.01, η²_p = 0.35, ŷ = 0.99). Estimated VO₂max increased significantly after CSRT in both trained groups (P < 0.001), but not in control groups (P > 0.05). There was no significant main effect of age (F = 2.69, P = 0.11, η²_p = 0.07, ŷ = 0.36) in VO₂max between groups at P2.

Growth hormone response
There was a significant main effect of age for GH (F = 17.47, P < 0.01, η²_p = 0.34, ŷ = 0.98) and GH AUC (F = 18.26, P < 0.01, η²_p = 0.35, ŷ = 1.00) (Table 2).

### Table 1. Wingate outcomes and physiological parameters determined before (P1) and after (P2) training.

|                         | YT (n = 10) | YC (n = 9) | MAT (n = 10) | MAC (n = 9) |
|-------------------------|------------|-----------|-------------|-------------|
| W_peak (W)              |            |           |             |             |
| P1                      | 1016 ±126² ⁵ | 1000±312³ | 885 ±155⁴   | 887 ±102   |
| P2                      | 1050±123²   | 944 ±246⁶ | 997±145⁵    | 824 ±113   |
| W_mean (W)              |            |           |             |             |
| P1                      | 584 ±58    | 500±93    | 434±86      | 445±37     |
| P2                      | 598 ±71    | 473±80.6  | 563±67      | 402±80     |
| VO₂max (mL min⁻¹·kg⁻¹)  |            |           |             |             |
| P1                      | 42.2±6.1⁴  | 43.8±5.1  | 39.8±9.5⁴   | 38.5±3.2   |
| P2                      | 45.5±5.7⁵  | 42.1±3.2  | 45.6±11.2⁶  | 40.1±3.8   |
| La_peak (mmol·l⁻¹)      |            |           |             |             |
| P1                      | 14.6±2.2⁷  | 13.9±3.4  | 13.4±2.7⁸   | 13.2±3.2   |
| P2                      | 16.1±2.3⁶  | 14.3±3.3  | 15.1±2.6⁸   | 13.3±3.1   |

Data are means ±SD; Maximal Power (W_peak); mean power (W_mean) in absolute values (W); Peak lactate concentration (La_peak); Maximal oxygen uptake (VO₂max); young trained (YT); young control (YC); middle-aged trained (MAT); middle-aged control (MAC); before training (P1); after training (P2).

⁵a significant differences from before and after training, ⁵α: P < .05.
⁵b significant differences between MAT and MAC, ⁵b: P < .05.
⁵c Significant differences between YT and YC, ⁵c: P < .05.
⁵d significant differences between YT and MAT, ⁵d: P < .05.
⁵e significant differences between YC and MAC, ⁵e: P < .05.

https://doi.org/10.1371/journal.pone.0183184.t001
Significantly higher GH was observed at rest, after warm-up, immediately post- and 10 min post-WAnT in the young groups as compared to the middle-aged groups at P1 (P < 0.05). This main effect of age was not present in GH<sub>0</sub> or GH<sub>w</sub> between MAT and YT at P2 (P > 0.05).

There was a main effect of time for GH (F = 17.83, P < 0.01, \( \eta^2_p = 0.34, \omega = 0.98 \)) and GH AUC (F = 10.83, P < 0.01, \( \eta^2_p = 0.34, \omega = 0.93 \)). For YT, GH<sub>0</sub>, GH<sub>end</sub>, and GH<sub>10</sub> were significantly higher at P2 compared to P1 (P < 0.05). For MAT, GH<sub>0</sub>, GH<sub>end</sub>, GH<sub>w</sub>, and GH<sub>10</sub> were significantly greater at P2 as compared to P1 (P < 0.05). We observed no significant changes from P1 to P2 for GH in control groups (P > 0.05).

We observed significant interaction between the Time×Group (F = 7.55, P = 0.01, \( \eta^2_p = 0.18, \omega = 0.76 \)). GH<sub>0</sub> and GH<sub>10</sub> (both P < 0.01) were significantly higher in YT compared to YC at P2. GH<sub>0</sub>, GH<sub>end</sub>, and GH<sub>10</sub> were significantly higher in MAT compared to MAC at P2 (P < 0.05).

### IGFBP-1 response

A significant main effect of Wingate-time (F = 203.19, P < 0.01, \( \eta^2_p = 0.86, \omega = 1.00 \)) was observed in all groups (Table 3).

At P1 and P2, IGFBP-1 increased throughout the progression of the WAnT in all groups (P < 0.05), i.e., from IGFBP-1<sub>0</sub> to IGFBP-1<sub>10</sub>. In addition, significant interaction between Wingate-Time×Age (F = 16.25, P < 0.001, \( \eta^2_p = 0.32, \omega = 1.00 \)) Wingate-Time×Group (F = 3.57, P = 0.02, \( \eta^2_p = 0.10, \omega = 0.78 \)), Wingate-Time×Time (F = 12.82, P < 0.001, \( \eta^2_p = 0.27, \omega = 1.00 \)), Wingate-Time×Time×Group (F = 5.00, P < 0.001, \( \eta^2_p = 0.13, \omega = 0.91 \)), and Wingate-Time×Time×Group×Age (F = 3.71, P = 0.01, \( \eta^2_p = 0.10, \omega = 0.79 \)) were observed in IGFBP-1.

We observed a significant main effect of age for IGFBP-1 (F = 42.08, P < 0.01, \( \eta^2_p = 0.55, \omega = 1.00 \)) and IGFBP-1 AUC (F = 41.02, P < 0.01, \( \eta^2_p = 0.50, \omega = 1.00 \)). IGFBP-1 was significantly higher at all phases of the WAnT in young as compared to middle-aged groups at P1 (P < 0.05). However, this age effect was not present at P2 (P > 0.05 between YT and MAT), whilst, for the control groups, the main effect of age remained statistically significant at P2 (P < 0.01). A main effect of time was observed in IGFBP-1 AUC (F = 30.42, P = 0.01, \( \eta^2_p = 0.17, \omega = 1.00 \)). Significantly greater IGFBP-1<sub>w</sub> and IGFBP-1<sub>end</sub> in YT, and IGFBP-1<sub>10</sub>, IGFBP-1<sub>w</sub>, and IGFBP-1<sub>end</sub> was observed at P2 compared to YT at P1.

### Table 2. GH concentration (ng ml<sup>-1</sup>) determined before (P1) and after (P2) training.

|        | GH<sub>0</sub> ± SD | GH<sub>w</sub> ± SD | GH<sub>end</sub> ± SD | GH<sub>10</sub> ± SD | GH AUC ± SD |
|--------|---------------------|--------------------|----------------------|---------------------|--------------|
| YT (n = 10) |                     |                    |                      |                    |              |
| P1     | 0.33±0.21<sup>a,b</sup> | 8.65±2.26<sup>a</sup> | 12.49±4.57<sup>a,d</sup> | 12.51±5.55<sup>d</sup> | 256.90±39.70<sup>a,d</sup> |
| P2     | 0.71±0.39<sup>c</sup> | 9.42±4.11<sup>a</sup> | 14.46±5.45<sup>a,d</sup> | 16.74±5.36<sup>a,c,d</sup> | 309.91±175.11 |
| YC (n = 9) |                     |                    |                      |                    |              |
| P1     | 0.32±0.30<sup>a</sup> | 8.60±1.44<sup>a</sup> | 12.66±3.79<sup>e</sup> | 13.31±5.22<sup>e</sup> | 262.60±59.22<sup>a</sup> |
| P2     | 0.45±0.03<sup>a</sup> | 8.83±3.93<sup>a</sup> | 13.10±2.17<sup>a</sup> | 14.33±8.89<sup>a</sup> | 267.20±70.04<sup>a</sup> |
| MAT (n = 10) |                   |                    |                      |                    |              |
| P1     | 0.24±0.31<sup>a</sup> | 5.78±3.10<sup>a</sup> | 8.15±4.23<sup>a</sup> | 9.06±3.33<sup>a</sup> | 187.33±36.80<sup>a</sup> |
| P2     | 0.85±0.94<sup>a</sup> | 8.75±2.97<sup>a</sup> | 10.78±1.73<sup>b</sup> | 12.97±2.26<sup>b</sup> | 262.91±46.72<sup>a</sup> |
| MAC (n = 9) |                   |                    |                      |                    |              |
| P1     | 0.13±0.01<sup>a</sup> | 5.99±3.96<sup>a</sup> | 9.02±3.30<sup>a</sup> | 9.64±2.52<sup>a</sup> | 191.71±65.62<sup>a</sup> |
| P2     | 0.14±0.03<sup>a</sup> | 8.15±2.40<sup>a</sup> | 10.60±1.75<sup>a</sup> | 11.39±1.66<sup>a</sup> | 208.50±17.73<sup>a</sup> |

Data are means ±SD; plasma GH concentration at rest (GH<sub>0</sub>); after warm-up (GH<sub>w</sub>); at the end of exercise (GH<sub>end</sub>); during recovery (GH<sub>10</sub>); GH AUC: Area under the curve (ng ml<sup>-1</sup> per min), young trained (YT); young control (YC); middle-aged trained (MAT); middle-aged control (MAC); before training (P1); after training (P2) and training

<sup>a</sup> significant differences from before and after training, \( a, P < 0.05 \).

<sup>b</sup> significant differences between MAT and MAC, \( b, P < 0.05 \).

<sup>c</sup> Significant differences between YT and YC, \( c, P < 0.05 \).

<sup>d</sup> significant differences between YT and MAT, \( d, P < 0.05 \).

<sup>e</sup> significant differences between YC and MAC, \( e, P < 0.05 \).

https://doi.org/10.1371/journal.pone.0183184.t002
### Table 3. IGF-1 concentrations (ng ml⁻¹) determined before (P1) and after (P2) training.

|      | IGF-1₀  | IGF-1₁ | IGF-1₁₀ | IGF-1 AUC |
|------|---------|--------|---------|----------|
| YC (n = 9) |         |        |         |          |
| P1   | 327.60±137.54 | 383.80±169.02 | 417.91±172.67 | 678.81±117.33 | 1376.70±442.50 |
| P2   | 340.90±130.97 | 436.79±176.65 | 556.63±136.98 | 749.87±113.10 | 1588.71±4034.13 |
| YT (n = 10) |       |        |         |          |
| P1   | 340.22±154.48 | 323.65±135.19 | 433.73±113.92 | 465.40±58.12 | 1384.60±2541.70 |
| P2   | 361.78±139.09 | 353.18±146.30 | 443.82±100.05 | 528.12±118.73 | 1299.4±3763.70 |
| MAT (n = 10) |      |        |         |          |
| P1   | 157.10±54.0  | 223.78±53.25 | 292.55±61.62 | 300.44±58.11 | 8379.40±1172.31 |
| P2   | 191.00±66.42 | 268.11±70.56 | 458.39±71.78 | 392.03±84.64 | 10403.32±1032.53 |
| MAC (n = 9) |      |        |         |          |
| P1   | 150.89±87.83 | 257.58±46.14 | 358.89±75.70 | 401.58±78.95 | 9077.52±1363.22 |
| P2   | 153.88±59.25 | 210.43±44.97 | 238.29±38.88 | 331.73±40.52 | 7951.21±1192.63 |

Data are means ±SD; plasma IGF-1 concentration at rest (IGF-1₀); after warm-up (IGF-1₁); at the end of exercise (IGF-1₁₀); during recovery (IGF-1 AUC). IGF-1 AUC: Area under the curve (ng ml⁻¹ per min), young trained (YT); young control (YC); middle-aged trained (MAT); middle-aged control (MAC); before training (P1); after training (P2).

- a significant differences from before and after training, a: P < .05.
- b significant differences between MAT and MAC, b: η² = 0.05.
- c Significant differences between YT and YC, c: P < .05.
- d significant differences between YT and MAT, d: P < .05.
- e significant differences between YC and MAC, e: P < .05.

### Table 4. IGFBP-3 concentrations (ng ml⁻¹) determined before (P1) and after (P2) training.

|      | IGFBP-3₀ | IGFBP-3₁ | IGFBP-3₁₀ | IGFBP-3 AUC |
|------|----------|----------|-----------|------------|
| YC (n = 9) |         |        |          |            |
| P1   | 4072±389 | 4019±422 | 4220±333 | 4100±449 | 132162±12088 |
| P2   | 4163±328 | 4211±405 | 4330±350 | 4349±396 | 13174±8902 |
| YT (n = 10) |        |        |          |            |
| P1   | 3749±403 | 3886±358 | 4012±384 | 3677±373 | 122502±12087 |
| P2   | 3788±349 | 3826±305 | 4022±335 | 3632±348 | 122455±5192 |
| MAT (n = 10) |       |        |          |            |
| P1   | 3060±389 | 3743±290 | 3596±295 | 3579±372 | 112767±8871 |
| P2   | 4130±416 | 4010±294 | 3951±238 | 3936±391 | 124857±6672 |
| MAC (n = 9) |      |        |          |            |
| P1   | 3373±403 | 3613±332 | 3789±366 | 3775±383 | 111005±7022 |
| P2   | 3332±379 | 3648±328 | 3763±357 | 3731±375 | 111860±9854 |

Data are means ±SD; plasma IGFBP-3 concentration at rest (IGFBP-3₀); after warm-up (IGFBP-3₁); at the end of exercise (IGFBP-3₁₀); during recovery (IGFBP-3 AUC). IGFBP-3 AUC: Area under the curve (ng ml⁻¹ per min), young control (YC); middle-aged trained (MAT); middle-aged control (MAC); before training (P1); after training (P2)

- a significant differences from before and after training, a: P < .05.
- b significant differences between MAT and MAC, b: η² = 0.05.
- c Significant differences between YT and YC, c: P < .05.
- d significant differences between YT and MAT, d: P < .05.
- e significant differences between YC and MAC, e: P < .05.

There was a significant main effect of Wingate-Time (F = 13.50, P < 0.01, η² = 0.28, Ngu = 1.00). At P1 and P2, IGFBP-3 increased throughout the progression of the WAnT in all groups (P < 0.05), i.e., from IGFBP-3₀ to IGFBP-3₁₀ (Table 4).
There was a significant main effect of age for IGFBP-3 (F = 25.57, P < 0.01, $\eta^2_p = 0.43$, $\omega = 1.00$). Significantly higher basal IGFBP-3 was observed for YT and YC compared to MAT and MAC at P1 (P = 0.001 and P = 0.002 respectively). However, this main effect of age was not observed at P2 (i.e., between YT and MAT at P2; P > 0.05).

Significant increases in IGFBP-3 were observed in MAT at rest (P = 0.001) and during warm-up (P = 0.003) at P2 compared to P1. When compared to control groups, IGFBP-3$_0$, IGFBP-3$_{end}$, and IGFBP-3$_{10}$ were significantly higher in trained groups compared to control groups at P2 (P < 0.05). In fact, a main effect of group was also observed (F = 14.12, P < 0.01, $\eta^2_p = 0.29$, $\omega = 0.95$).

**IGF-1/IGFBP-3 ratio**

The IGF-1/IGFBP-3 ratio was affected by Wingate-time (F = 130.27, P < 0.01, $\eta^2_p = 0.79$, $\omega = 1.00$). Post-hoc Bonferroni adjustments indicated the ratio increased significantly (P < 0.05) from rest to the end of exercise in all groups at P1 and P2, i.e. from IGF-1/IGFBP-3$_0$ to IGF-1/IGFBP-3$_{10}$ (Fig 1).

A main effect of age (F = 25.57, P < 0.01, $\eta^2_p = 0.43$, $\omega = 1.00$) was observed for IGF-1/IGFBP-3 at P1 and was significantly higher at all phases of the WAnT in young compared to middle-aged groups (P < 0.05). However, this age effect was not present following CSRT (P > 0.05 between YT and MAT), whilst, for control groups, the main effect of age remained statistically significant at P2 (P < 0.01). Significant interactions were observed between Age×Group (F = 14.29, P < 0.01, $\eta^2_p = 0.30$, $\omega = 1.00$). CSRT induced significant increases in IGF-1/IGFBP-3$_w$ and IGF-1/IGFBP-3$_{end}$ in YT, and increases in IGF-1/IGFBP-3$_{10}$ and IGF-1/IGFBP-3$_{end}$ in MAT (P < 0.05). When compared to control groups, significantly higher IGF-1/IGFBP-3$_{end}$ were observed in MAT as compared to MAC at P2 (P < 0.05) with significant interactions observed between Time×Group (F = 32.82, P < 0.01, $\eta^2_p = 0.49$ and $\omega = 1.00$).

**Correlative analysis**

Before training, a significant positive correlation existed between GH$_0$ and W$_{peak}$ for YT (r = 0.563, P = 0.003). GH$_{end}$ was also positively correlated with W$_{peak}$ at P1 (r = 0.792, P = 0.001) and P2 (r = 0.710, P < 0.001) in MAT, but only at P2 in YT (r = 0.268, P = 0.002).

**Discussion**

The primary finding of the present investigation is that 13 weeks’ CSRT induced a significant increase in W$_{peak}$ in both YT and MAT which ameliorated the effect of age between these groups. Increased sprint performance was associated with increased GH at rest, in response to the WAnT, and during recovery in YT and MAT, whilst IGF-1 and IGFBP-3 increased at rest in MAT only. Prior to CSRT, an effect of age was observed in GH, IGF-1, IGFBP-3, and IGF-1/IGFBP-3 basally and in response to exercise. However, CSRT ameliorated this age effect as both training groups (MAT and YT) had comparable basal GH and GH AUC, IGF-1$_{end}$ and IGF-1 AUC, and IGF-1/IGFBP-3.

The results of the AUC analysis for GH and IGF-1 suggest CSRT produce prolonged elevations in these hormones in response to the WAnT. Moreover, the increased IGF-1/IGFBP-3 ratio in response to exercise in trained groups suggests that there may be more unbound IGF-1 available for hormone-receptor interactions.

GH increases are associated with improvements in lean body mass and reduced fat mass [67] which was supported by the present investigation. In the current study, trained groups exhibited a trend for greater FFM at P2 (~0.9–1.7kg increases) and significantly less fat mass...
Fig 1. [IGF-1]/[IGFBP-3] ratio changes determined before (P1; above) and after (P2; below) training. Plasma [IGF-1]/[IGFBP-3] ratio at rest (t₀), after warm-up (tₚ), at the end of exercise (tₑ), and during recovery (t₁₀) in young trained (YT), young control (YC), middle-aged trained (MAT), and middle-aged control (MAC) groups. Data are presented as mean ± standard error for clarity.

https://doi.org/10.1371/journal.pone.0183184.g001
which may increased oxidative capacity as more active tissue would permit a greater oxygen uptake [68].

Our observation of increased estimated VO$_{2\text{max}}$ of ~16% following CSRT is in line with previous investigators who report increased cardiopulmonary fitness following high intensity training [69, 70]. In their recent review, Sloth et al. [71] suggested short term sprint interval training performed alone induces increases of 4.2–13.4% VO$_{2\text{max}}$ in young adult males. Therefore, the combination of sprint interval training with strength exercise appears a pragmatic approach to improve aerobic capacity in young and middle-aged subjects. These adaptations may be explained by increased enzymatic activity and mitochondrial mass [71–73]. However, a mechanistic explanation is outside the scope of this investigation.

As increased aerobic capacity is associated with increased blood lactate during intense efforts [54, 74], the higher blood lactate observed in trained groups may be due to increased ATP hydrolysis leading to greater lactate efflux in the plasma compartment as supported previously [53, 75].

CSRT produced a significant increase in W$_{\text{peak}}$ in trained groups, which supports several studies that report anaerobic training leading to enhanced power production in young [76] and older [77, 78] subjects. Interestingly, we found a positive correlation between serum growth factors and physical performance alterations, providing further associative evidence linking growth factors to improved muscle power [79].

In the present study, training-induced increases in basal GH occurred between trained groups, and ameliorated the age effect at P2. Such findings are in accordance with recent investigations demonstrating that intense training increases GH in males [80, 81]. However, other studies have not observed perturbations to basal GH after sprint [34, 82, 83] or resistance [83] training performed alone. The relatively short half-life of GH and the "snapshot" nature of basal hormone sampling may explain discrepancies in result, as GH during rest loses half of its physiologic activity in 10-30 minutes following secretion [84]. This brief period of hormonal activity depends on several factors such as diet, sleep duration, blood sampling (stress response from the vascular puncture) and time of the day [20, 84] which contributes to fluctuations in basal GH.

The most reproducible pulse of GH secretion however, occurs in response to intense exercise, when rate of secretion exceeds rate of degradation [85]. For example, Nevill et al. [34] reported GH to be tenfold higher than basal levels in sprinters following exercise and were greater than those measured in endurance athletes. GH increases may also be exercise volume dependent as 30s all-out sprints resulted in greater GH response than 6 s sprints and remained high for >90 minutes compared to 60 min following 6 s sprint [86]. An alternative explanation for discrepancies with previous investigations is the utilisation of concurrent training in the present study, rather than only resistance or only sprint training previously investigated.

GH anabolic actions are mostly mediated through IGF-1 and include regulation of whole body protein synthesis and breakdown [20]. Interestingly, the increased GH AUC following CSRT was associated with increase in IGF-1 AUC in YT and MAT suggesting that CSRT is a potent stimulus of the GH/IGF-1 axis. Data from the present investigation are in agreement with some [87] but not all [88] previous investigations in reporting increased basal IGF-1 following exercise training. For example, Cooper, Taaffe [76] reported comparable IGF-1 in masters runners and minimally exercising men aged 60–70 yrs (129±10 ng·ml$^{-1}$ and 124±11 ng·ml$^{-1}$, respectively). Differences in exercise modality and participant characteristics may explain discrepancies in findings, as the present investigation studied the influence of CSRT in young and middle-aged, rather than older, men as in the aforementioned investigation.

Whilst increased systemic IGF-1 is generally considered to confer an anabolic advantage, a recent investigation [89] reported decreased systemic IGF-1 following 12 weeks’ resistance exercise in older adults (74±6yrs), despite increased lean mass. These authors concluded that, during periods of active muscle building, IGF-1 is redistributed from circulation into tissue. Moreover, increased IGF-1 was observed without significant alteration in IGFBP-3 AUC in MAT following CSRT. IGFBP-
3 is known to enhance IGF-1 retention in the circulation and block its access to the cognate receptor (IGF-1R)\cite{15, 16}. The effect of intense training on IGFBP3 in elderly is still conflicting \cite{90}, and further investigation in large population is needed to better understand its variability over time in response to intense training.

There is sufficient evidence that anabolism in the elderly are intimately tied to alterations in GH/IGF-1 axis and declines in total and free IGF-1 response \cite{91}. Nevertheless, CSRT appears to reduce this age-related effect on IGF-1/IGFBP-3 (a surrogate for IGF-1 bioavailability) between trained groups at rest, at the end of WAnT, and during recovery with important increases at all phases following the WAnT. IGF-1 bioavailability appears a strong predictor on the effectiveness of the IGF-1 action \cite{92} and its increase confirms improvements of GH/IGF-1 axis in young and middle-aged trained men with training.

**Conclusion**

In conclusion, 13 weeks’ CSRT improved peak power output and body composition in young and middle-aged military men. This training intervention increases circulating GH in trained groups at rest and in response to exercise. Training-induced increases in basal GH occurred with amelioration of the age effect between trained groups. GH improvements in middle-aged men were associated with increased IGF-1 levels following CSRT. These were associated with increased IGF-1 bioavailability index in young and middle-aged trained groups following training. As such, CSRT appears to counteract the aging effect of somatotropic hormones.

**Acknowledgments**

The authors thank all the experts, doctors and officers of the Military Hospital of Instruction of Tunis and the General Direction of the Military Health for their participation in this experimental work.

**Author Contributions**

**Conceptualization:** MS.

**Data curation:** MS HD AC.

**Formal analysis:** WD FR.

**Funding acquisition:** MS.

**Investigation:** MS HD AC.

**Methodology:** MS AC.

**Project administration:** MS AC.

**Resources:** MS HD.

**Software:** MS WD HD.

**Supervision:** MS AC.

**Validation:** MS WD LDH JP FR HD AC.

**Visualization:** MS WD LDH JP FR HD AC.

**Writing – original draft:** MS LDH.

**Writing – review & editing:** MS WD LDH JP FR HD AC.
References

1. Frontera WR, Hughes VA, Lutz KJ, Evans WJ. A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. Journal of applied physiology. 1991; 71(2):644–50. PMID: 1938738
2. Fleg JL, Lakatta EG. Role of muscle loss in the age-associated reduction in VO2 max. Journal of applied physiology. 1988; 65(3):1147–51. PMID: 3192464
3. Korhonen MT, Mero A, Suominen H. Age-related differences in 100-m sprint performance in male and female master runners. Medicine and science in sports and exercise. 2003; 35(8):1419–28. https://doi.org/10.1249/01.MSS.0000790880.15333.CA PMID: 12900699.
4. Gent DN, Norton K. Aging has greater impact on anaerobic versus aerobic power in trained masters athletes. Journal of sports sciences. 2013; 31(1):97–103. https://doi.org/10.1080/02640414.2012.721561 PMID: 22974317.
5. Sipila S, Nanci M, Kjaer M, Pollanen E, Atkinson RA, Hansen M, et al. Sex hormones and skeletal muscle weakness. Biogerontology. 2013; 14(3):231–45. Epub 2013/05/03. https://doi.org/10.1007/s10522-013-9425-8 PMID: 23636830.
6. Hayes LD, Scuthorpe N, Herbert P, Baker JS, Spagna R, Grace FM. Six weeks of conditioning exercise increases total, but not free testosterone in lifelong sedentary aging men. The Aging Male. 2015; 18(3):195–200. https://doi.org/10.3109/13685538.2015.1046123 PMID: 26900699.
7. Hermann M, Berger P. Hormonal changes in aging men: a therapeutic indication? Experimental gerontology. 2001; 36(7):1075–82. PMID: 11404052
8. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrine reviews. 1993; 14(1):20–39. https://doi.org/10.1210/edrv-14-1-20 PMID: 8491152
9. Kim T, Chang JS, Kim H, Lee KH, Kong ID. Intense Walking Exercise Affects Serum IGF-1 and IGFBP3. Journal of lifestyle medicine. 2015; 5(1):21. https://doi.org/10.15280/jlm.2015.5.1.21 PMID: 26528426
10. RUTANEN E-M, PEKONEN F, MÄKINEN T. Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. The Journal of Clinical Endocrinology & Metabolism. 1988; 66(1):173–80.
11. Giovannini S, Cesari M, Marzetti E, Leeuwenburgh C, Maggio M, Pahor M. Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile. The journal of nutrition, health & aging. 2010; 14(6):457–60.
12. Baxter RC, Martin JL. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. Journal of Clinical Investigation. 1986; 78(6):1504. https://doi.org/10.1172/JCI112742 PMID: 2431001
13. Olivecrona H, Hilding A, Ekström C, Barle H, Nyberg Br, Möller C, et al. Acute and Short-Term Effects of Growth Hormone on Insulin-Like Growth Factors and Their Binding Proteins: Serum Levels and Hepatic Messenger Ribonucleic Acid Responses in Humans 1. The Journal of Clinical Endocrinology & Metabolism. 1999; 84(2):553–60.
14. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily 1. Endocrine reviews. 1999; 20(6):761–87. https://doi.org/10.1210/edrv.20.6.0382 PMID: 10605625
15. Naspi A, Panasiti V, Abbate F, Roberti V, Devirgiliis V, Curzio M, et al. Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo. PloS one. 2014; 9(6):e98641. https://doi.org/10.1371/journal.pone.0098641 PMID: 24905466
16. Codner E, Mericq V, Ugarte F, Iniguez G, Espinoza M, Avila A, et al. Usefulness of the measurement of insulin-like growth factor (IGF)-I and IGF-1 binding protein-3 (IGFBP-3) for the diagnosis of growth hormone (GH) deficiency in children. Revista medica de Chile. 1999; 127(7):807–13. PMID: 10668288
17. Birzniece V, Nelson AE, Ho KK. Growth hormone and physical performance. Trends in Endocrinology & Metabolism. 2011; 22(5):171–8.
18. Blackman MR, Sorkin JD, Münzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. Jama. 2002; 288(18):2282–92. PMID: 12425705
19. Veloso C. Regulation of muscle mass by growth hormone and IGF-I. British journal of pharmacology. 2008; 154(3):557–68. https://doi.org/10.1038/bjp.2008.153 PMID: 18500379
20. Cappon J, Brasel J, Mohan S, Cooper D. Effect of brief exercise on circulating insulin-like growth factor I. Journal of applied physiology. 1994; 76(6):2490–6. PMID: 7928875
21. Manetta J, Brun JF, Maimoun L, Callis A, Prefaut C, Mercier J. Effect of training on the GH/IGF-I axis during exercise in middle-aged men: relationship to glucose homeostasis. American Journal of...
23. Wideman L, Weltman JY, Hartman ML, Veldhuis JD, Weltman A. Growth hormone release during acute and chronic aerobic and resistance exercise. Sports medicine. 2002; 32(15):987–1004. PMID: 12457419

24. Godfrey RJ, Madgwick Z, Whyte GP. The exercise-induced growth hormone response in athletes. Sports medicine. 2003; 33(8):599–613. PMID: 12797841

25. Elio F, Antonelli G, Gatti R, Chiappini S, Spinella P, Cappellen E. Effects of two different types of exercise on GH/IGF axis in athletes. Is the free/total IGF-I ratio a new investigative approach? Clinica Chimica Acta. 2008; 387(1):71–4.

26. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Medicine and science in sports and exercise. 2010; 42(1):58–66. https://doi.org/10.1249/MSS.0b013e3181b07d2d PMID: 20010129

27. Salvadori A, Fanari P, Marzullo P, Codecasa F, Tovaglieri I, Cornacchia M, et al. Dynamics of GH secretion during incremental exercise in obesity, before and after a short period of training at different work-loads. Clinical endocrinology. 2010; 73(4):491–6. https://doi.org/10.1111/j.1365-2265.2010.03837.x PMID: 20550528

28. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinology and metabolism clinics of North America. 1996; 25(3):699–717. PMID: 8879994

29. Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clinical endocrinology. 2006; 65(4):413–22. https://doi.org/10.1111/j.1365-2265.2006.02676.x PMID: 16984231

30. Mazzotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nature Reviews Endocrinology. 2013; 9(5):265–76. https://doi.org/10.1038/nrendo.2013.5 PMID: 23381030

31. Zouhal H, Jacob C, Delamarche P, Gratas-Delamarche A. Catecholamines and the effects of exercise, training and gender. Sports medicine. 2008; 38(5):401–23. PMID: 18416594

32. Zouhal H, Vincent S, Moussa E, Botcazou M, Delamarche P, Gratas-Delamarche A. Early advancing age alters plasma glucose and glucoregulatory hormones in response to supramaximal exercise. Journal of Science and Medicine in Sport. 2009; 12(6):652–6. https://doi.org/10.1016/j.jsams.2008.03.003 PMID: 18547864

33. Sellami M, Ben Abderrahman A, Kebsi W, De Sousa MV, Zouhal H. Effect of sprint and strength training on glucoregulatory hormones: Effect of advanced age. Experimental Biology and Medicine. 2017; 242(1):113–23. https://doi.org/10.1177/1535370216662711 PMID: 27470931

34. Nevill ME, Holmyard DJ, Hall GM, Allsop P, van Oosterhout A, Burrin JM, et al. Growth hormone responses to treadmill sprinting in sprint- and endurance-trained athletes. European journal of applied physiology and occupational physiology. 1996; 72(5–6):460–7. PMID: 8925817.

35. Poehlman ET, Rosen CJ, Copeland KC. The influence of endurance training on insulin-like growth factor-I in older individuals. Metabolism. 1994; 43(11):1401–5. PMID: 7526125

36. Vitelli MV, Wilkinson CW, Merriam GR, Moe KE, Prinz PN, Ralph DD, et al. Successful 6-month endurance training does not alter insulin-like growth factor-I in healthy older men and women. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 1997; 52(3):M149–M54.

37. Borst SE, De Hoyos DV, Garzarella L, Vincent K, Pollock BH, Lowenthal DT, et al. Effects of resistance training on insulin-like growth factor-I and IGF binding proteins. Medicine and science in sports and exercise. 2001; 33(4):648–53. PMID: 11283443

38. Adams K, O’Shea JP, O’Shea KL, Climstein M. The effect of six weeks of squat, plyometric and squat-plyometric training on power production. The Journal of strength & conditioning research. 1992; 6(1):36–41.

39. Reaburn P, Logan P, Mackinnon L. Serum Testosterone Response to High-Intensity Resistance Training in Male Veteran Sprint Runners. The Journal of Strength & Conditioning Research. 1997; 11(4):256–60.

40. Kotzamanidis C, Chatzopoulos D, Michailidis C, Papaiaikou G, Patikas D. The effect of a combined high-intensity strength and speed training program on the running and jumping ability of soccer players. The Journal of Strength & Conditioning Research. 2005; 19(2):369–75.

41. Baekke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. The American journal of clinical nutrition. 1982; 36(5):936–42. PMID: 7137077.

42. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. British journal of nutrition. 1974; 32(01):77–97.
43. Åstrand P-O, Ryhming I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse rate during submaximal work. Journal of applied physiology. 1954; 7(2):218–21. PMID: 13211501

44. Vandewalle H, Peres G, Heller J, Monod H. All out anaerobic capacity tests on cycle ergometers. European journal of applied physiology and occupational physiology. 1985; 54(2):222–9. PMID: 4043052

45. Swain DP, Abernathy KS, Smith CS, Lee SJ, Burn SA. Target heart rates for the development of cardiorespiratory fitness. Medicine and science in sports and exercise. 1994; 26(1):112–6. PMID: 8133731

46. Botcazou M, Jacob C, Gratas-Delamarche A, Vincent S, Bentué-Ferrer D, Delamarche P, et al. Sex effect on catecholamine responses to sprint exercise in adolescents and adults. Pediatric exercise science. 2007; 19(2):132–44. PMID: 17603137

47. Moussa E, Zouhal H, Vincent S, Prioux J. Effect of sprint duration (6 s or 30 s) on plasma glucose regulation in untrained male subjects. Journal of sports medicine and physical fitness. 2003; 43(4):546. PMID: 14767419

48. Jacob C, Zouhal H, Prioux J, Gratas-Delamarche A, Bentué-Ferrer D, Delamarche P. Effect of the intensity of training on catecholamine responses to supramaximal exercise in endurance-trained men. European journal of applied physiology. 2004; 91(1):35–40. https://doi.org/10.1007/s00421-003-1002-4 PMID: 14614627

49. Derbré F, Vincent S, Maitel B, Jacob C, Delamarche P, Delamarche A, et al. Androgen responses to sprint exercise in young men. International journal of sports medicine. 2010; 31(05):291–7.

50. Zouhal H, Gratas-Delamarche A, Bentué-Ferrer D, Rannou F, Granier P, Delamarche P. Plasma catecholamine responses during a supramaximal exercise in endurance trained. Sex differences? Science & Sports. 1998; 3(13):112–8.

51. Zouhal H, Gratas-Delamarche A, Rannou F, Granier P, Bentué-Ferrer D, Delamarche P. Between 21 and 34 years of age, aging alters the catecholamine responses to supramaximal exercise in endurance trained athletes. International journal of sports medicine. 1999; 20(06):343–8.

52. Zouhal H, Jacob C, Rannou F, Gratas-Delamarche A. Effect of training status on the sympathoadrenal activity during a supramaximal exercise in human. Journal of sports medicine and physical fitness. 2001; 41(3):330. PMID: 11535563

53. Sellami M, Abderrahman AB, Casazza GA, Kebsi W, Lemoine-Morel S, Bouguerra L, et al. Effect of age and combined sprint and strength training on plasma catecholamine responses to a Wingate-test. European journal of applied physiology. 2014; 114(5):969–82. https://doi.org/10.1007/s00421-014-2828-7 PMID: 24500570.

54. Driss T, Vandewalle H. The measurement of maximal (anaerobic) power output on a cycle ergometer: a critical review. BioMed research international. 2013; 2013.

55. Dotan R, Bar-Or O. Load optimization for the Wingate anaerobic test. European journal of applied physiology and occupational physiology. 1983; 51(3):409–17. PMID: 6685039

56. Patton JF, Murphy MM, Frederick F. Maximal power outputs during the Wingate anaerobic test. International journal of sports medicine. 1985; 6(02):82–5.

57. Winter EM, Jones AM, Davison RR, Bromley PD, Mercer TH. Sport and Exercise Physiology Testing Guidelines: Volume I–Sport Testing: The British Association of Sport and Exercise Sciences Guide: Routledge; 2006.

58. Jaafar H, Rouis M, Attiogbe E, Vandewalle H, Driss T. A Comparative Study between the Wingate and Force–Velocity Anaerobic Cycling Tests: Effect of Physical Fitness. International journal of sports physiology and performance. 2016; 11(1):48–54. https://doi.org/10.1123/ijssp.2015-0063 PMID: 25849068

59. Ayalon A, Inbar O, Bar-Or O. Relationships among measurements of explosive strength and anaerobic power. Biomechanics IV: Springer; 1974. p. 572–7.

60. Dotan R, Bar-Or O. Climatic heat stress and performance in the Wingate Anaerobic Test. European journal of physiology and occupational physiology. 1986; 44(3):237–43. PMID: 7190918

61. Inbar O, Bar-Or O. Anaerobic characteristics in male children and adolescents. Medicine and science in sports and exercise. 1986; 18(3):264–9. PMID: 3523102

62. Padulo J, Laflay G, Chauauchi A, Chamari K. Bench press exercise: the key points. The Journal of sports medicine and physical fitness. 2015; 55(8):604–8. PMID: 24323345.

63. Padulo J, Laflay G, Ardigo LP, Chamari K. Concentric and eccentric: muscle contraction or exercise? Journal of human kinetics. 2013; 37(1):5–6.

64. Padulo J, Mignogna P, Mignardi S, Tonni F, D’ottavio S. Effect of different pushing speeds on bench press. International journal of sports medicine. 2012; 33(05):376–80.

65. de Salles BF, Simao R, Miranda F, Novaes Jda S, Lemos A, Willardson JM. Rest interval between sets in strength training. Sports medicine. 2009; 39(9):765–77. https://doi.org/10.2165/11315230-000000000-00000 PMID: 19691365.
86. Stokes K, Nevill M, Hall G, Lakomy H. The time course of the human growth hormone response to a 6 s and a 30 s cycle ergometer sprint. Journal of sports sciences. 2002; 20(6):487–94. https://doi.org/10.1080/02640410252925152 PMID: 12137178

87. Tsai C-L, Wang C-H, Pan C-Y, Chen F-C. The effects of long-term resistance exercise on the relationship between neurocognitive performance and GH, IGF-1, and homocysteine levels in the elderly. Frontiers in behavioral neuroscience. 2015;9.

88. Wieczorek-Baranowska A, Nowak A, Michalak E, Karolkiewicz J, Pospieszna B, Rutkowski R, et al. Effect of aerobic exercise on insulin, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in overweight and obese postmenopausal women. The Journal of sports medicine and physical fitness. 2011; 51(3):525–32. Epub 2011/09/10. PMID: 21904293.

89. Arnarson A, Gudny Geirsdottir O, Ramel A, Jonsson PV, Thorsdottir I. Insulin-Like Growth Factor-1 and Resistance Exercise in Community Dwelling Old Adults. The journal of nutrition, health & aging. 2015; 19(8):856–60. Epub 2015/09/29. https://doi.org/10.1007/s12603-015-0547-3 PMID: 26412290.

90. HELLENIUS MLB, BRISMAR KE, BERGLUND BH, FAIRE UH. Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. Journal of internal medicine. 1995; 238(2):121–30. PMID: 7543131

91. Eliakim A, Nemet D, Cooper DM. Exercise, training, and the GH-IGF-I axis. The Endocrine System in Sports and Exercise Maiden (MA): Blackwell Publishing. 2005:165–79.

92. Kucera R, Topolcan O, Pecen L, Kinkorova J, Svobodova S, Windrichova J, et al. Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic. Clinica Chimica Acta. 2015; 444:271–7.